Subscribe Now Subscribe Today
Science Alert
 
FOLLOW US:     Facebook     Twitter
Blue
   
Curve Top
International Journal of Pharmacology
  Year: 2009 | Volume: 5 | Issue: 5 | Page No.: 319-322
DOI: 10.3923/ijp.2009.319.322
Evaluation of Preserving Efficacy for Different Cough Syrups Manufactured by Different Pharmaceutical Companies
M. Khanfar, R. Khalil and A. AbuJafal

Abstract:
The aim of the current investigation is to assess the efficacy of different preservatives ingredients of different expectorant cough syrups manufactured by different pharmaceutical companies by comparing the growth of five microorganisms of known quanta of S. aureus, E. coli, P. aeruginosa and C. albicans. The microorganisms were inoculated into syrup A (glycerol and propylene glycol), syrup B (propylene glycol and glycerin), syrup C (glycerin, propylene glycol and butyl paraben), syrup D (methyl paraben and probylparaben) and normal saline as a control. All microorganisms were taken from standard stock cultures and incubated for 24 h. Growth of microorganisms into syrup was compared by counting the CFUs from a subculture of inoculated syrup at zero, 3, 6, 12, 24 and 48 h intervals. The data showed that all the combinations of the preservatives in the four studied cough syrups behaved similarly in term of antimicrobial efficiency. The findings suggested that the preservatives mixtures of propylene glycol with glycerol or with glycerin or with butyl paraben preservatives as well as methyl paraben with probylparaben are acceptable clinically and have considerably antimicrobial activity against infectious bacteria during the 48 h studied period.
 [Fulltext PDF]   [Fulltext HTML]   [XML: Abstract + References]   [References]   [View Citation]  [Report Citation]
 RELATED ARTICLES:
  •    Assessment of the Preserving Efficacy of the Pharmaceutical Syrups to Identified Air-Borne Microorganisms
How to cite this article:

M. Khanfar, R. Khalil and A. AbuJafal, 2009. Evaluation of Preserving Efficacy for Different Cough Syrups Manufactured by Different Pharmaceutical Companies. International Journal of Pharmacology, 5: 319-322.

DOI: 10.3923/ijp.2009.319.322

URL: https://scialert.net/abstract/?doi=ijp.2009.319.322

 
COMMENT ON THIS PAPER
 
 
 

 

 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
 

Curve Bottom